• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Prostate Cancer
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for Prostate Cancer trials.

DOWNLOAD BROCHURE GET IN TOUCH

Effective solutions for advancing Prostate Cancer research

Prostate cancer is the most common cancer among men, but it can be treated successfully. Signant Health applies decades of clinical experience and deep expertise with prostate cancer, as well as innovative clinical technologies within our Signant SmartSignals suite, to optimize the quality and reliability of data generated, helping teams identify new therapies sooner.

Prostate Cancer-1

Why Signant Health

  • Optimize PROM Reliability & Expedite Study Start-up
  • Collect More Complete Patient Function Data
  • Prevent Waste and Reduce Shipments & Returns
  • Digitize Studies for End-to-end Accuracy and Visibility
  • Increase Patient Comprehension & Ease Burdens for Sites & Patients
  • Optimize PROM Reliability & Expedite Study Start-up

    Optimize PROM Reliability & Expedite Study Start-up

    Key endpoints in prostate cancer trials require reliable patient reported outcomes measurement (PROM) data. Signant’s pre-configured eCOA solution for oncology provides electronic, pre-validated prostate cancer instruments that help patients provide complete, accurate, and timely responses, improving PRO accuracy compared to paper and pencil. In addition, launching studies faster can help expand the reach and impact of potential therapies and treatments. Signant’s pre-configured eCOA solution enables 33% faster study start-up at 20% less cost
     

  • Collect More Complete Patient Function Data

    Collect More Complete Patient Function Data

    Help your study team collect accurate data about treatment effects on patient function. We integrate ActiGraph with our eCOA system to automatically collect sleep and activity data without additional burden on patients or sites. Study teams can view this data alongside COA data for a more complete evaluation of patient function.
     
     

  • Prevent Waste and Reduce Shipments & Returns

    Prevent Waste and Reduce Shipments & Returns

    Prostate cancer studies often involve multiple patient cohorts and complex dosing schedules. Another variable adding complexity, investigational products for prostate cancer studies can be expensive as well as limited in supply and shelf life. Signant’s RTSM system utilizes unique algorithms to implement complex randomization schemes rapidly as well as optimize lot usage and efficiency. We support your study with a project team of multidisciplinary clinical science and operations experts from launch to closeout.

     

     

  • Digitize Studies for End-to-end Accuracy and Visibility

    Digitize Studies for End-to-end Accuracy and Visibility

     While all of our solutions can be used as standalone tools, when combined they enhance the accuracy and efficiency of your prostate cancer study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.
     
     
     

  • Increase Patient Comprehension & Ease Burdens for Sites & Patients

    Increase Patient Comprehension & Ease Burdens for Sites & Patients

    Oncology studies are complex and treatments carry risks that should be understood by well-informed patients. Signant’s eConsent solution improves comprehension and patient experience while providing sites with important version control features that ensure up-to-date informed consent forms.
     
     
     
     

Comprehensive Oncology experience

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our Prostate Cancer trial resources
SOLUTION BROCHURE

Prostate Cancer Trial Solutions Overview


GET INSIGHTS
VIDEO

Prostate Cancer Trial Solutions


WATCH [2 MIN]
SOLUTION

Oncology Trial Solutions


 
LEARN MORE

eClinical solutions for Prostate Cancer trials

Ready to learn more?

Discover how Signant can support your current or upcoming prostate cancer trials. 

DOWNLOAD BROCHURE GET STARTED